You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

Male looking at himself in the mirror

Patient Identification and DDIs

Identifying Suitable Patients

Patients who express interest in less frequent dosing, may benefit from Q2M VOCABRIA▼(cabotegravir) + REKAMBYS▼(rilpivirine)

Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.1

When deciding who is right for VOCABRIA + REKAMBYS, it’s important to identify patients who can meet the clinical requirements and are ready to commit to the Q2M dosing schedule.1

Some patients will express interest and others may benefit from a discussion about any challenges they face with daily therapy such as fear of disclosure.2

alt text

Patient need and commitment

It is important to have a conversation to assess patient needs and willingness to commit to the VOCABRIA + REKAMBYS treatment schedule.

  • Has the patient expressed an interest in less-frequent dosing?
  • Could the patient benefit from long-acting treatment due to:
    • Concerns about disclosure?
    • Anxiety with staying adherent to oral ARVs?
    • The impact of daily medication as a reminder of their status and associated negative memories?
  • Is the patient able to commit to Q2M visits?
  • Does the patient understand the importance of adhering to the schedule?

ARV = Antiretroviral; Q2M = Every-2-months

alt text

Main clinical requirements1,3

  • Virologically suppressed adults (HIV-1 RNA <50 copies/mL)
  • No present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class
  • No contraindications or contraindicated concomitant therapies
  • VOCABRIA + REKAMBYS injection is not recommended during pregnancy unless the expected benefit justifies the potential risk to the foetus

INI = Integrase Inhibitor; NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor

Changing the experience of HIV Therapy

Contact us

Request a contact from a GSK/ViiV Representative
References
  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare; 2023. https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc
  2. de Los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenged associated with daily dosing HIV medications and their impact on indicators of quality of life: findings from the Positive Perspectives Study. AIDS Behav. Published online ahead of print: October 7, 2020. Doi:10.1007/s10461-020-03055-1.
  3. REKAMBYS: Summary of Product Characteristics. Janssen Healthcare; 2023. https://www.medicines.ie/medicines/rekambys-35258/spc

 Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor.
©2023 GSK group of companies. All rights reserved.

PM-IE-CBR-WCNT-230005
Date of preparation: September 2023